Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
1396.6(c) 1380.2(c) 1353.6(c) 1333.2(c) 1343.8(c) Last
3 685 439 5 584 756 7 961 446 9 386 511 5 895 669 Volume
-0.95% -1.17% -1.93% -1.51% +0.80% Change
More quotes
Financials
Sales 2020 34 651 M 45 220 M 45 220 M
Net income 2020 4 791 M 6 252 M 6 252 M
Net Debt 2020 22 730 M 29 662 M 29 662 M
P/E ratio 2020 13,9x
Yield 2020 5,95%
Sales 2021 35 752 M 46 657 M 46 657 M
Net income 2021 4 326 M 5 645 M 5 645 M
Net Debt 2021 20 973 M 27 370 M 27 370 M
P/E ratio 2021 15,6x
Yield 2021 5,96%
Capitalization 66 890 M 87 270 M 87 291 M
EV / Sales 2020 2,59x
EV / Sales 2021 2,46x
Nbr of Employees 99 437
Free-Float 91,3%
More Financials
Company
GlaxoSmithkline plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (52%): intended for respiratory diseases (67.5% of net sales), HIV infection (27.7%), immune system disorders (3.5%) ) and cancer (1,3%); - OTC and parapharmaceutical medicine (26.7%); - vaccines (21.2%); - other (0.1%). Net sales are distributed geographically as... 
Sector
Pharmaceuticals
Calendar
10/28 | 08:00amEarnings Release
More about the company
Notations Surperformance© of GlaxoSmithKline plc
Trading Rating : Investor Rating :
More Ratings
All news about GLAXOSMITHKLINE PLC
10/24To Find a Coronavirus Vaccine, GlaxoSmithKline Is -2-
DJ
10/24To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
DJ
10/23Canada to invest up to C$214 mln for research into domestic-made vaccines - P..
RE
10/23GLAXOSMITHKLINE : GSK - ViiV Healthcare presents continued positive findings fro..
AQ
10/23Noveome Biotherapeutics, Inc. Announces New Appointments to its Board of Dire..
AQ
10/23GLAXOSMITHKLINE PLC : quaterly earnings release
10/23GLAXOSMITHKLINE : Gets a Neutral rating from Credit Suisse
MD
10/22European cities plead for more flu shots as winter looms, pandemic rages
RE
10/22GLAXOSMITHKLINE : ViiV Healthcare presents positive new findings from two studie..
PU
10/22GLAXOSMITHKLINE : ViiV Healthcare presents continued positive findings from firs..
PU
10/22S.Korea sticks to flu vaccine plan despite safety fears after 25 die
RE
10/22Wall Street banks see rare payday bonanza in India despite pandemic
RE
10/22GLAXOSMITHKLINE PLC : Crossing thresholds
CO
10/21Number of South Koreans dying after flu shot rises, prompts vaccine worries
RE
10/21GLAXOSMITHKLINE : JP Morgan gives a Neutral rating
MD
More news
News in other languages on GLAXOSMITHKLINE PLC
10/23COVID-19 : le Canada annonce un accord pour un vaccin canadien
10/23GLAXOSMITHKLINE : Credit Suisse toujours neutre sur le dossier
10/23Credit Suisse belässt GlaxoSmithKline auf 'Neutral'
10/23GLAXOSMITHKLINE PLC : Veröffentlichung des Quartalsergebnisses
10/23GLAXOSMITHKLINE PLC : publication des résultats trimestriels
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 1 806,25 GBX
Last Close Price 1 343,80 GBX
Spread / Highest target 74,9%
Spread / Average Target 34,4%
Spread / Lowest Target -16,7%
EPS Revisions
Managers
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-24.46%87 270
JOHNSON & JOHNSON-0.43%382 350
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999